A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
Launched by NOVO NORDISK A/S · May 22, 2023
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Signed consent obtained before any study-related activities
- • Female 15-50 years of age at the time of signing consent
- • Currently or recently pregnant
- • Resident of country included in the study
- • Authorisation for her HCP(s) to provide data to the registry
- • Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition.
- • Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception
- Exclusion Criteria:
- • Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
- • Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Princeton, New Jersey, United States
London, , United Kingdom
Madrid, , Spain
Patients applied
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported